ERBB2 and neoplasm: Overexpression of HER2 or interaction with the ligand, neuroregulin1 (NRG1), promotes HER2:HER3 heterodimerization and subsequent phosphoinositide 3-kinase signaling, driving tumor cell proliferation and tumor growth [1, 3].